Our previous study has shown that a panel of 12 genes including ERCC1, hMLH1, ATM, CDKN2B (p15INK4B), p14ARF, CDKN2A (p16INK4A), RASSF1A, RUNX3, GATA6, NDRG2, PTEN, and RARβ might be useful in evaluation of glioma aggressiveness. This evidence concerns the gene CDKN2A and central nervous system cancer.